Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Adam Walsh
ROTH
Adam Walsh
Roth MKM
Wall Street Analyst
★★★☆☆
#1329
on 13Foresight · ranked by our own returns
56%
Success Rate
+5.8%
Average Return
9 of 16 calls profitable · -6.9% vs benchmark
📈 Across the calls we could measure, roughly 56% of Adam Walsh's ratings turned a profit when each position was held for 1 year — averaging +5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 1 Hold 0 Sell
Adam's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
BIOA
BioAge Labs, Inc.
 Jun 17, 2026 BUY Strong Buy
+138.3% avg upside
9 analysts
$36.00
73.40% Upside
 ·
INSM
Insmed
 Jun 08, 2026 BUY Strong Buy
+82.1% avg upside
36 analysts
$212.00
121.34% Upside
 +4.5%
EQ
Equillium
 Jun 02, 2026 BUY Strong Buy
+183.0% avg upside
14 analysts
$12.00
293.44% Upside
 -0.7%
VTVT
vTv Therapeutics
 May 13, 2026 BUY Strong Buy
-6.9% avg upside
12 analysts
$58.00
65.43% Upside
 +6.6%
ARCT
Arcturus Therapeutics
 May 08, 2026 BUY Buy
+291.8% avg upside
35 analysts
$20.00
165.52% Upside
 ·
RARE
Ultragenyx Pharmaceutical
 May 18, 2020 BUY Strong Buy
+142.0% avg upside
36 analysts
$82.00
198.88% Upside
 +53.5%
ASND
Ascendis Pharma
 Apr 20, 2020 BUY Strong Buy
+16.9% avg upside
24 analysts
$171.00
25.86% Downside
 -9.8%
LKFT
Lakefront Biotherapeutics
 Apr 08, 2020 BUY Hold
+272.9% avg upside
24 analysts
$298.00
952.91% Upside
 ·
CORT
Corcept Therapeutics
 Feb 10, 2020 HOLD Buy
-45.6% avg upside
15 analysts
 — +112.0%
KYNB
Kyntra Bio
 Nov 12, 2019 BUY Buy
+369.6% avg upside
14 analysts
$71.00
959.79% Upside
 +15.3%
ALDX
Aldeyra Therapeutics
 Jun 25, 2019 BUY Strong Buy
+716.1% avg upside
21 analysts
$25.00
1175.60% Upside
 -32.5%
PTGX
Protagonist Therapeutics
 May 08, 2019 BUY Strong Buy
-22.1% avg upside
19 analysts
$17.00
85.01% Downside
 +48.9%
GLMD
Galmed Pharmaceuticals
 Nov 05, 2018 BUY Buy
+4115.6% avg upside
13 analysts
$35.00
5934.42% Upside
 -58.3%
VRTX
Vertex Pharmaceuticals
 Jul 18, 2017 BUY Strong Buy
-2.7% avg upside
61 analysts
$182.00
59.62% Downside
 +37.0%
BMRN
BioMarin Pharmaceutical
 Mar 03, 2016 BUY Strong Buy
+72.7% avg upside
52 analysts
$107.00
95.70% Upside
 +4.9%
TSE:BHC
Bausch Health Companies
 Nov 30, 2015 BUY Buy
+783.6% avg upside
29 analysts
$226.31
3257.74% Upside
 ·
ALNY
Alnylam Pharma
 Jun 24, 2015 BUY Strong Buy
+23.4% avg upside
51 analysts
$160.00
42.37% Downside
 -56.1%
SRPT
Sarepta Therapeutics
 May 20, 2015 BUY Buy
+246.5% avg upside
49 analysts
$30.00
71.07% Upside
 -27.0%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Adam Walsh — Frequently Asked Questions
How accurate are Adam Walsh's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Adam's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, or -6.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Adam ranked on 13Foresight?
Adam Walsh is currently ranked #1329 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Adam cover?
Adam most recently has ratings on BIOA, INSM, EQ, VTVT, ARCT, RARE, ASND, LKFT, CORT, KYNB, ALDX, PTGX and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.